نتایج جستجو برای: tpa therapy

تعداد نتایج: 659243  

2005

Background Although coronary thrombosis plays a critical role in the pathogenesis of unstable angina and non-Q-wave myocardial infarction (NQMI), the effects of thrombolytic therapy in these disorders is not clear. Also, the role of routine early coronary arteriography followed by revascularization has not been established. Methods and Results Patients (n=1473) seen within 24 hours of ischemic ...

2013
Christian Foerch Nathanael L. Rosidi Frieder Schlunk Arne Lauer Flor A. Cianchetti Emiri Mandeville Ken Arai Kazim Yigitkanli Xiang Fan Xiaoying Wang Klaus van Leyen Helmuth Steinmetz Chris B. Schaffer Eng H. Lo

Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH). Surprisingly, however, the assumption that tPA will worsen ICH has never been biologically tested. Here, we assessed the effects of tPA in two models of ICH....

2017
Ike dela Peña Cesar Borlongan Guofang Shen Willie Davis

To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop stra...

Journal: :Stroke 2013
Yaoming Wang Zhen Zhao Nienwen Chow Padmesh S Rajput John H Griffin Patrick D Lyden Berislav V Zlokovic

BACKGROUND AND PURPOSE 3K3A-activated protein C (APC) protects young, healthy male rodents after ischemic stroke. 3K3A-APC is currently under development as a neuroprotectant for acute ischemic stroke in humans. Stroke Therapy Academic Industry Roundtable recommends that after initial studies in young, healthy male animals, further studies should be performed in females, aged animals, and anima...

Journal: :Stroke 2009
Wenlan Liu Jill Hendren Xu-Jun Qin Ke Jian Liu

BACKGROUND AND PURPOSE A major limitation of tissue plasminogen activator (tPA) thrombolysis for ischemic stroke is the narrow time window for safe and effective therapy. Delayed tPA thrombolysis increases the risk of cerebral hemorrhage and mortality, which, in part, is related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). We recently showed that normobaric hyperox...

2016
Jay Chol Choi Ji Sung Lee Tai Hwan Park Yong-Jin Cho Jong-Moo Park Kyusik Kang Kyung Bok Lee Soo Joo Lee Jae Guk Kim Jun Lee Man-Seok Park Kang-Ho Choi Joon-Tae Kim Kyung-Ho Yu Byung-Chul Lee Mi-Sun Oh Jae-Kwan Cha Dae-Hyun Kim Hyun-Wook Nah Dong-Eog Kim Wi-Sun Ryu Beom Joon Kim Hee-Joon Bae Wook-Joo Kim Dong-Ick Shin Min-Ju Yeo Sung Il Sohn Jeong-Ho Hong Juneyoung Lee Keun-Sik Hong

BACKGROUND AND PURPOSE About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. METHODS From a pr...

Journal: :Stroke 2014
Michael D Hill Andrew M Demchuk Mayank Goyal Tudor G Jovin Lydia D Foster Thomas A Tomsick Rüdiger von Kummer Sharon D Yeatts Yuko Y Palesch Joseph P Broderick

BACKGROUND AND PURPOSE The Interventional Management of Stroke (IMS)-III trial randomized patients with acute ischemic stroke to intravenous tissue-type plasminogen activator (tPA) plus endovascular therapy versus intravenous tPA therapy alone within 3 hours from symptom onset. A predefined secondary hypothesis was that subjects with significant early ischemic change on the baseline scan would ...

2005
M. L. Simoons E. Boersma Maarten L. Simoons Eric Boersma

In recent years different regimens for reperfusion therapy in evolving myocardial infarction have been developed: intravenous streptokinase, accelerated tPA and direct angioplasty. The life saving effect of thrombolytic therapy has been established in a number of randomized trials, most of which tested streptokinase 1.5 million units administered over l h. The results have been summarized in th...

2013
Shahriar Absar

SUMMARY In this study, we developed a thrombincleavable delivery system for tissue plasminogen activator (tPA) to attenuate bleeding complications associated with conventional thrombolytic therapy. tPA was conjugated with human serum albumin (HSA) via a thrombin-cleavable peptide (GFPRGFPAGGCtPA) (Fig. 1). The resulting camouflaged tPA construct has been designed to mask the enzymatic activity ...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2007
Li Zhang Zheng Gang Zhang Xian Shuang Liu Ann Hozeska-Solgot Michael Chopp

OBJECTIVE We tested the hypothesis that the phosphatidylinositol-3 kinase (PI3K)/Akt pathway mediates the neuroprotective effect of combination therapy of atorvastatin and tissue-type plasminogen activator (tPA) in rats after stroke. METHODS AND RESULTS Combination of atorvastatin (20 mg/kg) and tPA (10 mg/kg) significantly reduced ischemic lesion volume, whereas monotherapy with atorvastatin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید